Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-1b
- Development stage
- Unknown
- Lead developer
- 三元基因
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Inhalation
01
Overview
Yundeshu is a nebulized formulation of recombinant human interferon alfa-1b (rhIFN-α1b) developed by Beijing Sanyuan Gene Pharmaceutical. It is a type I interferon that binds to the interferon-alpha/beta receptor (IFNAR) complex, initiating the JAK-STAT signaling cascade. This activation leads to the induction of numerous interferon-stimulated genes (ISGs) that provide broad-spectrum antiviral activity, inhibit viral replication, and modulate the host immune response. Yundeshu is specifically investigated for the treatment of pediatric lower respiratory tract infections, including those caused by respiratory syncytial virus (RSV), pneumonia, and bronchiolitis, where direct delivery to the lungs via nebulization enhances local therapeutic efficacy.
- Brand names
- Yundeshu
- Other names
- recombinant human interferon alfa-1brhIFN-alpha1brhIFN-alpha-1brhIFN-alpha 1b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-1b.